Bausch + Lomb Launches SeeNa™ Optical Biometry and Topography System in the United States
System Captures Nine Key Measurements to Calculate IOL Power and Predict Lens Position
VAUGHAN, Ontario, Oct. 30, 2023 – Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of SeeNa, an ophthalmic diagnostic system for refractive cataract patients that is fully integrated with Bausch + Lomb’s Eyetelligence™ surgical planning software to help streamline surgical planning and information flow.
“SeeNa provides a new way for busy refractive cataract practices to enhance surgical planning efficiency,” said Luc Bonnefoy, president, Global Surgical, Bausch + Lomb. “Surgeons can gather critical measurements in a few steps, and the integrated Eyetelligence software connectivity combines these data points to help eliminate the need for multiple documents and avoid lost data and time.”
SeeNa captures nine key measurements necessary for evaluating patients’ eyes and determining the cataract intraocular lens (IOL) power calculation in one single step. It also offers a user-friendly interface, allowing clinicians and staff to quickly master acquisition and operation and receive results in seconds. The integrated Eyetelligence software connectivity allows for efficient upload of the measurements, enabling a seamless, secure flow of this data from the office to the operating room.
“In my busy practice, efficiency is paramount and every second counts. Having a device that captures all this information without the need to move patients to different rooms or machines will be a huge workflow advantage,” said Mark Lobanoff, M.D., director, refractive surgery, OVO LASIK + LENS, Minneapolis. “In addition, being able to integrate with Bausch + Lomb’s Eyetelligence software means that I can access all the data that I need for IOL selection and surgical planning in one place, whenever and wherever I need to.”
For more information, visit https://www.bauschsurgical.com/cataract/seena/.
###
About Eyetelligence
The Eyetelligence platform is a cloud-based application that was first launched in 2018 to allow surgeons to access their personal settings from any Stellaris Elite® vision enhancement system and provide first-in-class efficiency features for expedited technical service, assessment and customer support. In October 2023, the platform was expanded to include a new cloud-based planning software that streamlines surgical planning, information flow and enables electronic medical record and diagnostic device integration. For more information, visit
https://www.bauschsurgical.com/cataract/eyetelligence/.
About Bausch + Lomb
Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from the moment of birth through every phase of life. Its comprehensive portfolio of more than 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and commercial footprint with approximately 13,000 employees and a presence in nearly 100 countries. Bausch + Lomb is headquartered in Vaughan, Ontario with corporate offices in Bridgewater, New Jersey. For more information, visit www.bausch.com and connect with us on Twitter, LinkedIn, Facebook and Instagram.
Forward-looking Statements
This news release may contain forward-looking statements, which may generally be identified by the use of the words “anticipates,” “hopes,” “expects,” “intends,” “plans,” “should,” “could,” “would,” “will,” “may,” “believes,” “estimates,” “potential,” “target,” or “continue” and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in Bausch + Lomb’s filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch + Lomb undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.
© 2023 Bausch + Lomb.
SEN.0005.USA.23
Media Contact:
Kristy Marks
[email protected]
(908) 927-0683
Investor Contact:
George Gadkowski
[email protected]
(877) 354-3705 (toll free)
(908) 927-0735